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Abstract
Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells
(GSCs). GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets. We
determined that A20 (TNFAIP3),a regulator of cell survivaland the NF-kB pathway, is overexpressed in GSCs relative tonon-stem
glioblastomacellsatboth the mRNAand protein levels.Todeterminethe functional significanceof A20inGSCs,wetargetedA20
expression with lentiviral-mediated delivery of short hairpin RNA (shRNA). Inhibiting A20 expression decreased GSC growth and
survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA.
Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFa-induced cell death than
matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFa-mediated apoptosis. The decreased survival of
GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere
formation assays. The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice
bearing human glioma xenografts. In silico analysis of a glioma patient genomic database indicates that A20 overexpression and
amplification is inversely correlated with survival. Together these data indicate that A20 contributes to glioma maintenance
through effectsonthe glioma stem cell subpopulation.Although inactivatingmutations in A20in lymphoma suggest A20 canact
as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data
suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival. A20 anticancer therapies should
therefore be viewed with caution as effects will likely differ depending on the tumor type.
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Introduction
Tumors are aberrant organ systems that display a complex
interplay between neoplastic cells and recruited vascular, inflam-
matory, and stromal elements [1]. Cellular heterogeneity within
the neoplastic compartment has been modeled with complemen-
tary stochastic and hierarchical paradigms. Molecular signals that
drive tumor formation and maintenance frequently are shared
with normal development and wound responses, processes in
which normal stem and progenitor cells function [1–4]. Stem cell–
like cancer cells (or cancer stem cells) need not be derived from
normal stem cells but may be subjected to evolutionary pressures
that select for the capacity to self-renew extensively or differentiate
depending on conditions [1–5]. Cancer stem cells have been
derived from several primary brain tumors, but both their
derivation and characterization are incomplete and rapidly
expanding [6–35]. Glioblastoma (World Heath Organization
grade IV astrocytoma) is the most common primary brain tumor
in adults and one of the most aggressive and deadly cancers
[36,37]. Current glioblastoma therapies, including radiotherapy
and chemotherapy, are highly toxic, offering only palliation
[36,37]. Although brain tumor stem cells remain controversial due
to the evolving understanding of their nature, a number of reports
have demonstrated that glioblastomas contain cancer stem cells
and that these cells contribute to therapeutic resistance and tumor
angiogenesis [1–35]. Significant effort has been undertaken to
identify potential targets in cancer stem cells that promote tumor
maintenance and that might be amenable to disruption [35].
To identify molecular targets in cancer, the majority of analyses
completed to date compare bulk tumor to normal tissues and may
therefore underestimate the importance of genes and proteins
expressed within the cancer stem cell subpopulation. For example,
comparison of GSCs to non-stem glioma cells or bulk tumor has
resulted in greater understanding of the importance of HIF2a
[10], L1CAM [21], and Bmi-1 [22] for GSC tumorigenic capacity.
These proteins are all relatively overexpressed in glioblastoma
stem cells (GSCs) and now known to regulate GSC growth,
survival, and self-renewal [10,21,22]. These biological processes
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mediators of cancer such as c-myc [23] and AKT [24–26].
Together, these studies demonstrate that isolation and character-
ization of GSCs can define new molecular targets for cancer
therapy and determine novel roles for established signaling
pathways in cancer stem cell biology.
We speculated that the cell survival and NF-kB regulator A20,
or Tumor Necrosis Factor a inducible protein 3 (TNFAIP3), was
one molecular target with a greater role in glioma than currently
understood [38,39]. An oncogenic role for A20 is suggested by
the increased A20 expression in some cancers: A20 is elevated in
undifferentiated nasopharyngeal carcinoma [40], poorly differ-
entiated head and neck cancers [40], gliomas [41], and
inflammatory breast cancer [42]. Increased A20 expression in
breast cancer cells confers resistance to TNFa [43,44] and
tamoxifen [45], suggesting A20 mediates survival and chemore-
sistance. Although these data imply a protumorigenic role for
A20, gene expression and functional studies in other cancer types
suggest A20 is a tumor suppressor. Deletions and inactivating
mutations have been identified in B-cell lymphoma, Hodgkin
lymphomas, and non-Hodgkin lymphomas [46–51]. In addition,
decreased A20 was associated with resistance to DNA-damaging
agents in glioma cells [52]. Together, these data indicate that the
role of A20 in cancer biology may be context and tissue-type
dependent and is an important areaf o rf u r t h e ri n v e s t i g a t i o n .
Evidence from the A20 null mice also suggested a link to stem cell
biology: the epidermal and dermal layers of A20
2/2 mice are
significantly thicker than that of wild-type controls, demonstrat-
ing A20 regulates skin cell fate [53]. Based on these data, we
examined the role of A20 in cancer stem cell biology in gliomas.
We determined A20 is elevated in GSCs where it is required to
maintain growth and survival. Importantly, we find increased
A20 mRNA expression or copy number is associated with poor
glioma patient survival.
Results
A20 Is Highly Expressed in Glioma Stem Cells
To determine whether A20 could differentially contribute to
glioma biology through the recently identified glioma subfractions,
we utilized several complementary methods to evaluate A20
expression in freshly isolated GSC-enriched and -depleted cultures
derived using our previously published methodology
[11,12,15,21,23,25]. To determine whether A20 was differentially
expressed at the transcript level, total mRNA was collected and
analyzed by quantitative real-time PCR. We found GSC-enriched
cells isolated from short-term xenografts expressed elevated A20
mRNA levels in comparison to matched non-stem glioma cells
(Figure 1A). We had previously confirmed that these cells self-
renew and propagate tumors in an immunocompromised host
[11,12,21,23]. As in our past studies, the GSCs also express high
levels of the glioma stem cell marker encoded by Olig2 (Figure 1B).
Consistent with these results, GSCs isolated directly from patient
specimens also expressed elevated levels of A20 and Olig2
(Figure 1C). To determine whether elevated A20 mRNA
expression correlated with increased A20 protein levels, we next
visualized A20 expression using immunofluorescence (Figure 1D
and 1E). Increased expression of A20 was observed in GSCs in
comparison to matched non-stem glioma cells (Figure 1D). GSCs
form neurospheres when cultured in serum-free media. When
single neurospheres were sectioned, we determined A20 was
coexpressed with the stem cell transcription factor Sox2
(Figure 1E). To confirm these results, we enriched or depleted
GSCs from either short-term xenografts or patient tumor
specimens and isolated lysates for immunoblotting (Figure 1F;
Figure S1). In every tumor tested, GSCs displayed strikingly
elevated A20 levels compared to matched non-stem cells. Similar
to results with mRNA, the differential expression of A20 was true
whether subfractions were isolated from patient specimens
passaged short term in immunocompromised mice or directly
from patient specimens (Figure 1F; Figure S1).
To further evaluate whether cells expressing a GSC marker also
highly express A20 at the single-cell level in a quantitative manner,
we performed flow cytometric analysis with cells double labeled for
A20 and CD133. We confirmed that A20 is highly coexpressed
with the glioma stem cell marker CD133 (Prominin-1) when cells
were isolated from a patient specimen passaged short term in
immunocompromised mice (Figure 2A) or directly isolated from
patient specimens (Figure 2B; Figure S2A and S2B). When bulk
tumor cells were analyzed for expression of CD133 and A20,
greater than 75% of CD133+ cells were also A20+, whereas less
than 10% of CD1332 cells were A20+ (Figure 2C; Figure S2A
and 2SB). The percentage of CD133+ cells is also higher in the
A20+ subpopulation: greater than 50% of A20+ cells were
CD133+, whereas less than 8% of A202 cells were CD133+
(Figure 2D; Figure S2C and S2D). Coexpression of CD133 and
A20 also occurred when cells were cultured short term in vitro
after enrichment or depletion of GSCs from a xenografted patient
specimen (Figure S2C and S2D). Together, these data strongly
support elevated expression levels of A20 in GSCs.
Expression of shRNA Directed against A20 Decreases GSC
Growth and Survival
Although our findings demonstrated A20 was consistently up-
regulated in GSCs, no studies to date have suggested a functional
role for A20 in cancer stem cells. As A20 was linked to cell survival
in some reports [53–57], we first assessed the ability of A20 to
regulate GSC cell growth and apoptosis by targeting A20
expression using lentiviral transduced short hairpin RNAs
(shRNAs) (Sigma Mission shRNA). To control for potential off-
target shRNA effects, two different sequences of shRNA directed
against A20 and a nontargeting shRNA were used when cell
numbers permitted. Transduction with A20 shRNA reduced A20
protein levels in GSCs in comparison to the nontargeting control,
Author Summary
Glioblastomas are the most common and aggressive
primary brain tumors in adults, with a median survival of
only 12–15 months. Glioblastomas display a cellular
hierarchy with a subset of cells having stem cell–like
properties, including the capacity to self-renew and
propagate tumors. Specific ablation of cancer stem cells
is widely thought to be critical for effective and long-
lasting treatment of cancers. We report the identification
of the antiapoptotic protein A20 (which is also known as
TNFAIP3) as a novel regulator of glioma stem cell survival.
Glioma stem cells overexpress A20 relative to non-stem
glioma cells, and this protects them from cell death,
whereas depletion of A20 attenuates glioma stem cell
survival and tumor growth. Interrogation of a molecular
glioma database reveals that A20 levels correlate with
decreased survival in patients. These data indicate that A20
is a tumor enhancer in the context of glioma, which
importantly contrasts with its known function as a tumor
suppressor in the context of lymphoma. Therefore, A20
may be a context-specific regulator of cancer stem cell
survival and growth.
A20 Is a Glioma Stem Cell Target
PLoS Biology | www.plosbiology.org 2 February 2010 | Volume 8 | Issue 2 | e1000319Figure 1. A20 expression is elevated in glioma stem cells. (A) A20 mRNA expression is elevated in GSCs isolated from T4121 and T3359 glioma
patient specimens passaged short term in immunocompromised mice in comparison to matched non-stem glioma cells. An asterisk (*) indicates p,0.05
with t-test comparison of glioma stem cells and non-stem glioma cells isolated from the same tumor. (B) Isolated glioma stem cells utilized in (A) express
increased mRNA levels of the GSC marker Olig2 in comparisontomatched non-stem glioma cells. An asterisk (*)indicates p,0.01witht-test comparison of
glioma stem cells and non-stem glioma cells isolated from the same tumor. (C) A20 mRNA expression is elevated in GSCs isolated from a CCF2045 patient
specimen passaged in comparison tomatched non-stem glioma cells. An asterisk (*)indicates p,0.05witht-test comparison of glioma stem cells and non-
stem glioma cells isolated from the same tumor. (D) Immunofluorescent staining of isolated glioma stem cells from a T4105 glioma patient specimen
passaged short term in immunocompromised mice demonstrates increased A20 protein expression in comparison to matched non-stem glioma cells. (E)
Immunofluorescent staining demonstrates A20 expression in neurospheres that also express the stem cell transcription factor Sox2. (F) Western blot
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targeting profoundly impacted GSC growth as demonstrated by a
marked reduction in cell numbers over time (Figure 3C and 3D).
In contrast, A20 knockdown minimally altered the growth patterns
of non-stem glioma cells (Figure S3A and S3B). The differential
dependence of A20 in GSCs and non-stem cells can be further
demonstrated by analysis of the relative effect of A20 shRNA on
cell growth (Figure S3C–S3F). To determine whether the
decreased growth of GSCs with A20 knockdown was associated
with changes in the cell cycle, we performed flow cytometric
analysis with DNA content determination. Cellular entry into S
phase was decreased with A20 targeting (Figure 3E), supporting a
role for A20 in proliferation. We also observed an increase in the
percentage of cells in the SubG0 phase of the cell cycle (Figure 3F)
Figure 2. Flow cytometry demonstrates A20 colocalizes with a glioma stem cell marker. (A and B) Flow cytometry of fixed bulk tumor cells
isolated from T08-837 short-term xenograft or directly from a CW468 patient specimen demonstrates significant co-staining of the glioma stem cell
marker CD133 and A20. Representative FACS plots are shown for T08-837 (A) and CW468 (B). (C) When the percentage of A20+ cells is determined in
the CD1332 and CD133+ fractions, significantly higher percentages of A20+ cells are present in the CD133+ fraction. (D) When the percentage of
CD133+ cells is determined in the A202 and A20+ fractions, significantly higher percentages of CD133+ cells are present in the A20+ fraction. An
asterisk (*) indicates p,0.001 with t-test comparison of the indicated samples.
doi:10.1371/journal.pbio.1000319.g002
analysis demonstrates glioma stem cells isolated from glioma specimens passaged short term in immunocompromised mice (T3359, T4105, T3832) or
directly from patient specimens (T066002, T0076037,T0148042)expressmore A20than matched non-stem glioma cells. Expression of theglioma stem cell
marker Olig2 is elevated in isolated glioma stem cells. Tubulin expression demonstrates equivalent protein loading.
doi:10.1371/journal.pbio.1000319.g001
A20 Is a Glioma Stem Cell Target
PLoS Biology | www.plosbiology.org 4 February 2010 | Volume 8 | Issue 2 | e1000319and a consistent, but relatively modest, 1.1–1.3-fold increase in G1
phase cell cycle arrest (unpublished data). Thus, knockdown of
A20 inhibits cell growth due in part to decreased proliferation
associated with increased cell death and cell-cycle arrest.
As changes in the cell cycle suggest that A20 regulates cell
survival, we evaluated apoptosis with complementary assays.
Annexin V assays detect phosphatidylserine expression on the cell
surface, a process that occurs during apoptosis and other forms of
Figure 3. Targeting A20 decreases glioma stem cell growth. (A and B) Western analysis demonstrates that infection of glioma stem cells
isolated from a T4121 (A) orT08-837 (B) patient specimen passaged short term in immunocompromised mice with lentivirus expressing shRNA
directed against A20 decreases A20 protein expression in comparison to infection with lentivirus expressing nontargeting (NT) shRNA. Tubulin
expression demonstrates equivalent protein loading. (C and D) Cell counts with Trypan Blue staining demonstrates that decreasing expression of A20
reduces the growth of glioma stem cells isolated from T4121 (C) or T08-836 (D) patient specimens passaged short term in immunocompromised
mice. An asterisk (*) indicates p,0.05 with ANOVA comparison of nontargeting shRNA to A20 shRNAs. (E) Cell-cycle analysis demonstrates that
targeting A20 expression decreases the percentage of cells in the S phase of the cell cycle in glioma stem cells isolated from T4121, T08-837, and
T4597 cells patient specimen passaged short term in immunocompromised mice. An asterisk (*) indicates p,0.05 with t-test comparison of
nontargeting shRNA control and A20 shRNA. (F) Cell-cycle analysis demonstrates that targeting A20 expression increases the percentage of cells in
the SubGo phase of the cell cycle in isolated T4121, T08-837, and T4597 GSCs. An asterisk (*) indicates p,0.05 with t-test comparison of nontargeting
shRNA control and A20 shRNA.
doi:10.1371/journal.pbio.1000319.g003
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PLoS Biology | www.plosbiology.org 5 February 2010 | Volume 8 | Issue 2 | e1000319Figure 4. Targeting A20 decreases glioma stem cell survival. (A) Annexin V staining demonstrates increased apoptosis with A20 targeting in
glioma stem cells isolated from a D317 glioma xenograft or a T3359 patient specimen passaged short term in immunocompromised mice. An asterisk
(*) indicates p,0.01 with t-test comparison of nontargeting (NT) shRNA control and A20 shRNA. (B) Annexin V staining demonstrates increased
apoptosis with A20 targeting in tumor subfractions isolated from a T0066-002 patient specimen. An asterisk (*), p,0.05 with ANOVA comparison of
nontargeting shRNA control to the indicated A20 shRNA. (C) Caspase activity relative to cell number as determined in the cell titer assay increased in
A20 shRNA infected glioma stem cells isolated directly from a T0066-022 patient specimen, but not in matched non-stem glioma cells. An asterisk (*)
indicates p,0.05 with t-test comparison of non-targeting shRNA control to A20 shRNA. (D) Caspase activity relative to cell number as determined in
the cell titer assay increased in A20 shRNA infected glioma stem cells isolated from a T3359 patient specimen passaged short-term in
immunocompromised mice. An asterisk (*) indicates p,0.05 with ANOVA comparison of non-targeting shRNA control to the indicated A20 shRNA. (E)
TUNEL staining demonstrates increased apoptosis in A20 infected glioma stem cells isolated from a T4105 patient specimen passaged short term in
immunocompromised mice. (F) Targeting A20 in GSCs isolated from CCF1863 or T3359 patient specimens passaged short term in
immunocompromised mice decreased phosphorylation of p65/RelA on Serine 536 as determined via Western blot analysis.
doi:10.1371/journal.pbio.1000319.g004
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glioma xenografts (Figure 4A) and directly from a patient
specimen (Figure 4B), introduction of A20-directed shRNA
increased the percentage of Annexin V–positive cells when
compared to nontargeting control shRNA. Caspases, including
caspase 3 and caspase 7, are cysteine-aspartic acid proteases that
are activated during apoptosis [5,58]. In GSCs isolated directly
from a patient specimen (Figure 4C) or from a human patient
specimen passaged short term in immunocompromised mice
(Figure 4D), caspase 3/7 activity normalized to cell number
increased with A20 targeting compared to control. Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining detects DNA fragments that occur in the last phase of
apoptosis [5,58]. Increased TUNEL staining was observed in
isolated GSCs with knockdown of A20 (Figure 4E). The potent
induction of apoptosis with A20 targeting was restricted to GSCs
as minimal effects were observed with decreased A20 expression in
matched non-stem glioma cells (Figure 4B–4D). Together, these
data demonstrate that targeting A20 in GSCs results in increased
apoptosis and suggest that A20 is a prosurvival factor for GSCs.
To evaluate the potential mechanism for the decreased survival
of GSCs with A20 targeting, we determined activation of p65/
RelA, a central component of NF-kB signaling [59–63].
Phosphorylation of RelA at Serine 536 is known to enhance the
transactivation potential of the NF-kB complex [62,63]. NF-kB
signals have been shown to be elevated in glioma [64], and
targeting RelA in glioma has been shown to decrease cell growth
[65]. We found that knockdown of A20 decreased the activating
phosphorylation of RelA without changes in total RelA levels
(Figure 4F). These data suggest that failure to maintain active
RelA in GSCs contributes, at least in part, to the decreased growth
and survival of GSCs with A20 knockdown.
Neurosphere Formation Capacity Is Decreased with A20
Targeting
Cancer stem cells are functionally defined through their
capacity for sustained self-renewal. As the growth and survival of
GSCs was affected by A20 knockdown, we next examined whether
A20 was important for self-renewal. To more definitively evaluate
this possibility, we utilized an in vitro indicator of self-renewal in
normal and cancer stem cells: the neurosphere assay [1–9,66–68].
We found that targeting A20 in GSCs decreased neurospheres
formation in comparison to cells transduced with nontargeting
control shRNA (Figure 5). A20 loss decreased the percentage of
wells with neurospheres in both primary (Figure 5A–5C) and
secondary (Figure 5C) passages. Neurospheres that did form from
A20-targeted GSCs were smaller than those forming from
nontargeted GSCs (Figure 5D–5E), suggesting decreased prolifer-
ation. Thus, the formation of neurospheres is significantly
hampered by the loss of A20, indicating a role for A20 in GSC
self-renewal.
A20 Protects GSCs from TNFa-Induced Apoptosis
According to the cancer stem cell hypothesis, GSCs and other
cancer stem cells are responsible for tumor maintenance and
recurrence after therapy due to the ability of these cells to survive
cellular assaults thatwould typically result in cell death [1–5]. For
example, GSCs have been shown to preferentially survive
radiotherapy [15,16], chemotherapy [17,18], treatment with
TNF-related apoptosis-inducing ligand (TRAIL) [19], and Fas-
induced apoptosis [20]. These data demonstrate GSCs are
resistant to a wide variety of prodeath signals. Prior studies
suggested that TNFa therapy may be beneficial for the treatment
of glioma due to the ability to promote apoptosis [69], but the
sensitivity of cancer stem cells to this effect has not been
determined. As A20 can inhibit TNF-induced apoptosis in some
cell types [43,44,53–57], and A20 levels are elevated in GSCs, we
hypothesized that GSCs are resistant to TNFa-induced apopto-
sis. We therefore investigated the effect of TNFa on the survival
of GSC-enriched and -depleted cultures. TNFa increased
apoptosis in non-stem glioma cells (Figure 6A and 6B), consistent
with prior results in glioma cell lines [70,71]. In contrast, GSCs
isolated from multiple human glioma xenografts were resistant to
TNFa-induced cell death (Figure 6A and 6B and unpublished
data). To determine the role of A20 in GSC TNFa apoptotic
resistance, GSCs were transduced with either shRNA directed
against A20 or nontargeting shRNA and subsequently treated
with TNFa. Consistent with our prior results (Figure 4), GSC
apoptosis was increased with targeting of A20 as measured with
caspase activity (Figure 6C; Figure S4A). This increase in
apoptosis was significantly enhanced when A20 knockdown cells
wereadditionally treatedwithTNFa (Figure6C; FigureS4A). To
determine whether the TNFa effects could differentially regulate
self-renewal in A20 knockdown cells, we evaluated neurosphere
formation in the presence and absence of A20 targeting and
TNFa treatments. We found that addition of TNFa in the
presence of A20 shRNA, but not nontargeting shRNA,
significantly decreased neurosphere formation (Figure 6D; Fig-
ure S4B). Together, these data indicate that GSCs are resistant to
TNFa-induced apoptosis in an A20-dependent manner and
further demonstrate A20 is an important prosurvival factor in
GSCs.
Targeting A20 Increases the Survival of Mice Bearing
Human Glioma Xenografts
Our results thus far determined an important role for A20 in
GSC growth, survival, and self-renewal in vitro, but the ultimate
goal of any cancer stem cell–directed therapy is to provide
therapeutic benefit in vivo. We therefore evaluated the ability of
A20 targeting to increase the survival of immunocompromised
mice bearing intracranially implanted human glioma cells. For
initial experiments, we performed an in vivo limiting dilution
assay with GSCs transduced with nontargeting control shRNA or
shRNA directed against A20. Tumor-bearing mice were allowed
to survive until the development of neurologic signs in each
animal (including lethargy, ataxia, paralysis, or seizure) in
accordance with Institutional Animal Care and Use Commit-
tee–approved protocols. For all cell numbers transplanted, the
median survival of mice injected with GSCs derived from either
T3359 (Figure 7A) or TB-08-0118 (Figure 7B) was increased with
A20 knockdown. When 300–1,000 cells were injected, the tumor
incidence also decreased when A20 was targeted (Figure 7A and
7B). Kaplan-Meier curves further demonstrate significant
increases in survival with introduction of A20 shRNA when
T3359 (Figure 7C) or TB-08-0118 (Figure 7D) GSCs were
injected. Although cells used in the in vivo studies displayed
successful targeting of A20 expression prior to implantation,
immunohistochemical analysis of A20 shRNA tumors that grew
o u ts h o w e dt h a tt h e s et u m o r se s c a p e dA20 knockdown (Figure
S5). In a separate experiment with T4105 cells in which all
animals were sacrificed simultaneously at the onset of the first
neurologic sign in any animal, infiltrating glioma cells were
observed in animals injected with GSCs infected with nontarget-
ing shRNA, but not A20-targeting shRNA (Figure 7E). These in
vivo data indicate that targeting A20 in GSCs can increase
survival in mouse models of human brain tumors and suggest
A20 could be a useful therapeutic target in glioma.
A20 Is a Glioma Stem Cell Target
PLoS Biology | www.plosbiology.org 7 February 2010 | Volume 8 | Issue 2 | e1000319Figure 5. A20 knockdown decreases neurosphere formation. (A and B) The percentage of wells with neurospheres is decreased in A20-infected
glioma stem cells isolated from a T4121 (A) or T08-837 (B) patient specimen passaged short term in immunocompromised mice were infected with A20
shRNA in comparison to nontargeting (NT) shRNA infected cells. An asterisk (*) indicates p,0.01 with t-test comparison of nontargeting control shRNA to
A20 shRNA.(C) The percentage of wells with neurospheres is decreasedin A20-infectedgliomastemcells isolated froma T4302 patient specimen passaged
short term in immunocompromised mice in primary and secondary passages. An asterisk (*) indicates p,0.05 with t-test comparison of nontargeting
control shRNA to A20 shRNA. (D and E) The average volume of spheres formed in neurosphere formation assays with glioma stem cells isolated from a
A20 Is a Glioma Stem Cell Target
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Correlates with Poor Survival
Our data in human glioma patient specimens and xenografts in
vitro and in vivo suggested that elevated A20 levels in GSCs are
protumorigenic. To extend these results into a clinical analysis, we
utilized two databases: the National Cancer Institute’s Repository
for Molecular Brain Neoplasia Data (REMBRANDT) and The
Cancer Genome Atlas (TCGA), which respectively contain
information from multiple brain tumor types or glioblastoma
only. Using REMBRANDT, we found that up-regulation of A20
mRNA 2-fold or greater in all glioma patients correlated with a
significant decrease in survival (Figure 8A). When the analysis was
restricted to Grade II or Grade III astrocytoma, A20 mRNA up-
regulation 2-fold or greater also significantly correlated with
decreased survival (Figure 8B). However, A20 mRNA up-
regulation did not correlate with survival in glioblastoma patients
in either REMBRANDT or TCGA (Figure 8C and unpublished
data). These data demonstrate that elevation of A20 in early
clinical stages of glioma correlates with poor survival, but
differences in A20 expression in the bulk tumor at the time of
glioblastoma diagnosis cannot predict survival. As global gene
expression analyses currently available in the public databases
cannot consider the contribution of the GSC subfraction, these
data may underestimate the importance of A20 in glioblastoma.
However, it remained possible that an overall elevation of A20 in
glioblastoma patients compared to lower grade astrocytomas
contributed to the poorer survival of glioblastoma patients. To
evaluate this possibility, we compared the median expression
intensity of A20 across tumor types in REMBRANDT. We found
elevated levels of A20 in glioblastoma compared to all other types
of brain tumors as well as control (nontumor) tissue (Figure 8D). As
elevated levels of mRNA may reflect an increase in gene copy
number, we sought to determine whether genomic changes in A20
occurred in glioma patients. Copy number REMBRANDT
analysis for A20 indicated that a 3-fold or greater amplification
of the 6q23.3 chromosomal region correlated with poor survival,
although the number of patients in this group was small (n=4;
Figure 8E). It is also important to note that, in contrast to
lymphoma [46–51], inactivating point mutations in A20 were not
identified in recently completed genetic screens of the glioma
genomes [72,73]. These data further suggest that A20 activity is
important for glioma development and biology. Overall, our data
demonstrate that A20 promotes the tumor initiating capacity of
GSCs and strongly suggests that increased A20 expression
contributes to poor glioma patient outcome.
Understanding the genetic and/or protein expression profile of
patients in which A20 is elevated may be important for elucidating
the mechanisms through which A20 is induced or the pathways
through which A20-expressing cells regulate survival. We
therefore utilized the TCGA glioblastoma database to evaluate
the presence of common glioblastoma mutations (Figure S6A and
S6B) and expression of TNFa signaling mediators (Figure S6C) in
patients with different levels of A20 expression. Tumors with TP53
and NF1 mutations were enriched in tumors with high A20
expression in comparison to tumors with intermediate or low A20
levels (Figure S6A and S6B). In contrast, the percentage of samples
with EGFR mutations was lowest in tumors with high A20
expression (Figure S6A and S6B). Further evaluation of expression
of TNFa signaling mediators in patients with differential A20 levels
demonstrated higher TNF receptor and RelB mRNA expression in
tumors with elevated A20 expression. These data suggest that A20
expression may be indicative of elevated TNFa or NF-kB signals.
As the effects of these two pathways on GSC pro-tumorigenic
behaviors are relatively unknown, more thorough evaluation of
their biologies in the context of cancer stem cells may be
warranted.
Discussion
Our appreciation of the complex interactions between cell types
during tumor initiation, progression, and recurrence continues to
grow with our increasing understanding of cancer biology.
Whereas researchers once considered tumors to be masses of
clonal cancer cells, the involvement of immune cells, endothelial
cells, and neighboring fibroblasts to tumor growth is now well
recognized [1]. We believe that the identification of cancer stem
cells with a probable concurrent stochastic clonality builds upon
this model to recognize a previously underestimated contribution
of the heterogeneity of tumor cells themselves [1–4]. By profiling
the molecular and biological properties of cancer stem cells, we
may therefore identify genes and proteins whose importance in
cancer was poorly recognized. We have now determined that the
inhibitor of apoptosis A20 is a cancer stem cell target. A20 was
elevated in GSCs in comparison to non-stem glioma cells at both
the mRNA and protein levels in cells isolated directly from glioma
patient specimens and human glioma xenografts. Targeting A20
expression with shRNA in GSCs significantly impaired their
growth and survival in vitro and increased tumor latency in mice
bearing human glioma xenografts. The importance of A20 to
human glioma patients is further demonstrated by the association
of elevated A20 levels with poor outcome.
Although current methods for cancer stem cell enrichment from
solid cancers have been sufficient to differentiate tumor subpopula-
tions, prospective identification of cancer stem cells has limitations
that contribute to the controversy surrounding their existence [1–35].
Due to the restricted amount of tissue often available after pathologic
review, it is difficult to generate enough patient-derived GSCs for the
majority of experiments without culture or amplification as a
xenograft. As we believe that microenvironmental conditions within
the tumor contribute to GSC maintenance [74], we utilize a
xenograftisolationsystemtoobtainsufficientGSCs,butvalidatedkey
studies with direct analysis of patient specimens. Experiments with
cells directly derived from primary glioma specimens would be
optimal, but results in GSCs from xenograft and patient-derived
specimens have, thus far, been similar [11,15]. Once tissue or
xenografts are obtained, enrichment or depletion of cancer stem cells
from the bulk tumor can be useful to respectively isolate glioma stem
cell and non-stem glioma cell fractions with the stipulation that both
GSC and non-stem glioma populations are heterogeneous and
unlikely to be mutually exclusive based on current sorting protocols
[1–4,27]. Fluorescence-activated cell sorting (FACS) sorting to enrich
for glioma stem cells has relied on the presence of the glycosylated
form of the cell surface marker CD133 (Prominin-1): a protein whose
role in tumorigenesis and glioma biology remains unclear [27].
However, CD133 is not the only marker useful for prospective
identification of glioma stem cells, not all CD133+ cells are GSCs,
and CD133 cannot exclusively segregate for tumorigenic potential
and self-renewal in all glioma patient samples and cell lines studied
[27–33]. The side population associated with ABCG2 transporter
activity has been shown to be an important segregator for
T3359 (D) or T4302 (E) patient specimen passaged short term in immunocompromised mice is decreased with infection of A20 shRNA in comparison to
nontargeting shRNA. Representative images of spheres used for analysis of volume are shown.
doi:10.1371/journal.pbio.1000319.g005
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PLoS Biology | www.plosbiology.org 9 February 2010 | Volume 8 | Issue 2 | e1000319Figure 6. A20 protects GSCs from TNFa-induced apoptosis. (A and B) The percentage of Annexin V–positive cells increases with TNFa
treatment of non-stem glioma cells, but not matched GSC-enriched cultures, isolated from a D456MG (A) or a T3359 (B) patient specimen passaged
short term in immunocompromised mice. An asterisk (*) indicates p,0.01 with ANOVA comparison to untreated non-stem glioma cells. A number
sign (#) indicates p,0.01 with ANOVA comparison of similarly treated non-stem glioma and glioma stem cells. (C) Targeting A20 in GSCs sensitizes to
TNFa-induced apoptosis. GSCs isolated from a T3790 glioma xenograft infected with nontargeting shRNA or shRNA directed against A20 were treated
with 5 ng/ml TNFa and relative caspase activity measured. An asterisk (*) indicates p,0.05 with ANOVA comparison to similarly treated non-targeting
control cells. A number sign (#) indicates p,0.05 with ANOVA comparison of TNFa to untreated cells infected with the same shRNA. (D) TNFa
augments decreases in neurosphere formation observed in GSCs with A20 targeting. Ten cells per well were plated in the neurosphere formation
assay and subsequently treated with 5 ng/ml TNFa. After 12 d, the number of neurospheres per well was assessed. An asterisk (*) indicates p,0.05
with ANOVA comparison of nontargeting control shRNA to A20 shRNA. A number sign (#) indicates p,0.05 with ANOVA comparison of control
versus TNFa-treated A20 shRNA-treated GSCs.
doi:10.1371/journal.pbio.1000319.g006
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PLoS Biology | www.plosbiology.org 10 February 2010 | Volume 8 | Issue 2 | e1000319Figure 7. Targeting A20 decreases glioma stem cell tumorigenic potential and increases the survival of mice bearing intracranial
human glioma xenografts. (A) Median survival of mice bearing human glioma xenografts increases when injected with A20 knockdown glioma
stem cells in comparison to nontargeting (NT) cells isolated from a T3359 patient specimen passaged short term in immunocompromised mice in the
in vivo limiting dilution assay. (B) Median survival of mice bearing human glioma xenografts increases when injected with A20 knockdown glioma
stem cells in comparison to nontargeting cells isolated from a T080118 patient specimen in the in vivo limiting dilution assay. (C) Kaplan-Meier curves
demonstrate increased survival with A20 targeting in Balbc nu/nu mice injected with 300 glioma stem cells isolated from a T3359 xenograft. An
asterisk (*) indicates p,0.05 with log-rank analysis of survival curves. (D) Kaplan-Meier curves demonstrate increased survival with A20 targeting
when 500 glioma stem cells isolated from a T080118 glioma patient specimen were injected into Balbc nu/nu mice. An asterisk (*) indicates p,0.05
with log-rank analysis of survival curves. (E) Representative images of brains of mice injected with T4105 GSCs infected with lentivirus expressing
nontargeting shRNA or shRNA directed against A20. For this experiment, all animals were sacrificed upon the development of the first neurologic sign
in any one mouse (a nontargeting shRNA animal). Hematoxylin and eosin staining demonstrated the presence of brain tumors in mice injected with
nontargeting shRNA infected GSCs, including the presence of glioma cells infiltrating normal brain. Gliomas were not observed in brains of mice
injected with A20 knockdown GSCs.
doi:10.1371/journal.pbio.1000319.g007
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PLoS Biology | www.plosbiology.org 11 February 2010 | Volume 8 | Issue 2 | e1000319Figure 8. A20 is a prognostic indicator in glioma patients. (A) Increased A20 mRNA expression was associated with reduced glioma patient
survival in REMBRANDT. Twenty-four patients exhibited a 2-fold elevation in mRNA, whereas 64 patients were classified as having down-regulated
expression and 130 with intermediate expression. An asterisk (*) indicates p,0.006 with log-rank analysis of survival curves for up-regulated versus
down-regulated expressing groups. (B) Increased A20 mRNA expression was associated with reduced astrocytoma patient survival in REMBRANDT.
Five patients exhibited a 2-fold elevation in mRNA, whereas 14 patients were classified as having down-regulated expression and 18 with
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gliomas without CD133 expression, the carbohydrate antigen SSEA-
1/CD15/LeX can enrich for tumor-initiating cells [32]. CD133 and
SSEA-1 separations are based on the use of antibodies against
unspecified carbohydrate modified epitopes, adding further com-
plexity by suggesting that posttranslational modifications to cell
surface proteins are important for cancer stem cell biology [27].
These data suggest that, similar to leukemias, no one cell surface
marker will be sufficient to isolate a homogeneous population of
cancer stem cells from solid tumors. It is therefore enticing to suggest
that molecular targets, such as A20, that are elevated in GSC-
enriched fractions may segregate for a cancer stem cell subpopula-
tion. Validating our findings in a model without dependence on
CD133, we characterized A20 expression in lines with tumor
enrichment in the SSEA-1+ fraction and found increased A20
expression (Figure S1). These results strongly suggest that A20
segregates with tumor initiating potential.
Our data with A20 expression suggest that, regardless of the cell
surface markers used for isolation, the tumor-maintaining glioma
subfractions may have common intracellular molecular targets.
Determining the direct contribution of A20 (or cells expressing other
identified nuclear targets such as HIF2a[11] and Bmi-1 [22]) is
limited by our inability to sort for live A20-positive cells due to its
intracellular localization. However, one recent study was able to
utilize an indirect reporter based method to further elucidate the role
of the transcription factor Oct4 in cancer stem cell biology. When the
Oct4 promoter was used to drive green fluorescent protein (GFP)
expression in osteosarcoma cells, reporter activity could identify
tumor-initiating cells [75]. Application of similar methodologies to
other cancer stem cell targets could permit the development of non-
cell surface marker based sorting techniques and lead to further
confirmation of the existence of cancer stem cells.
Although cancer stem cells can be isolated using different
methodologies, a common theme in cancer stem cell biology is the
ability of this tumor subpopulation to survive cellular assaults and
repopulate the tumor. To date, only a few molecular mechanisms
for GSC resistance to apoptotic signals have been identified. GSC
radioresistance is linked to elevated checkpoint activation and
DNA repair [15], whereas chemoresistance is associated with
improved drug efflux due to the presence of the ABCG2
transporter [24]. Resistance to TRAIL-induced apoptosis in GSCs
may be due to reduced levels of caspase 8 [19], and GSCs appear
to be less sensitive to Fas-induced apoptosis due to decreased levels
of oligomeric Fas [20]. Our data now add A20 as one of this
growing list of prosurvival mediators in GSCs. We find that
knockdown of A20 induces apoptosis in GSCs and sensitizes GSCs
to TNFa-induced apoptosis in cell culture, although we have not
measured apoptosis specifically in the GSC compartment in vivo.
Whether elevated levels of A20 in GSCs could also regulate other
forms of therapeutic resistance remains to be investigated, but it is
interesting to note that A20 was one of a set of genes identified as
mediators of resistance to O6-alkylating agents [52]. Cell lines
were derived from primary and recurrent tumors selected for
resistance to 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) or
temozolomide in media with 20% fetal calf serum [52]. Under
this prodifferentiating condition, down-regulation of A20 and the
established pluripotency gene leukemia inhibitory factor (LIF)
were both associated with chemoresistance [52]. Roles for A20
(our data) and LIF [34] in GSC self-renewal imply that elevation
of these proteins would be more likely to facilitate rather than
impede GSC mediated chemoresistance. These data reinforce the
notion that the differentiation state of the glioma cells may
differentially impact the mechanisms through which tumor cells
survive cellular stresses (i.e., conditional essentiality).
Our examination of A20 in the context of glioma heterogeneity
revealed A20 contributes to GSC protumorigenic behaviors, but
recent evidence in the literature suggests a tumor suppressive role
for A20 in other cancers. Although we find A20 is highly expressed
in GSCs and point mutations in A20 have not been identified in
glioma [72,73], A20 deletion and mutation is prevalent in
lymphoma [46–51]. A20 knockdown in GSCs promotes apoptosis
and reduces tumorigenic potential in mouse models of human
cancer, but overexpression of A20 in A20-deficient lymphoma cells
produces similar results [46,47]. Together, these data suggest that
A20 may be a tumor suppressor or a tumor enhancer depending on
the cancer type. Many molecular pathways, including the NF-kB
pathway which A20 can inhibit, may be either pro- or antitumori-
genic depending on the cellular context and tumor stage [59]. For
example, inhibition of NF-kB signals in mouse epidermis resulted in
squamous cell carcinomas [76], whereas a similar transgenic
strategy in transformed hepatocytes prevented tumor progression
to hepatocellular carcinoma [77]. A20 may similarly have
differential effects on tumor development or progression depending
on the biological requirements for A20 in specific tissues. Indeed,
unique roles for A20 in lymphoma and glioma tumor biology may
be anticipated based on differences in basal expression between
lymphoid tissues and the brain. In the majority of tissues, including
brain, A20 expression is induced by a variety of stimuli (TNFa,
lipopolysaccharide, interleukin-1), but unexpressed or expressed at
very low levels under basal conditions [53]. However, A20 is
constitutively expressed in lymphoid tissues, particularly the thymus
and lymph nodes where A20 is critical for suppression of
inflammatory responses mediated by NF-kB [53,57]. Mutation of
A20 may therefore be more beneficial during the development of
lymphoma. In contrast, our analysis suggests A20 levels increase
with brain tumor grade, suggesting a benefit for A20 elevation in
astrocytoma growth and linking A20 to glioma tumor progression.
Thus, the precise biological and molecular outcomes of targeting
A20 in each tumor type must be further defined, particularly before
broadly applying A20-based therapies for cancer treatment.
Our data implicate A20 as an important mediator of cancer
stem cell biology by demonstrating that A20 is involved in glioma
maintenance through the regulation of GSC growth and survival.
The increased survival of mice bearing intracranial tumors upon
A20 targeting, and the decreased survival of glioma patients with
elevated mRNA, both indicate that inhibition of A20 (or its
downstream mediators) may be beneficial for glioma therapy.
However, the increased survival of mice upon A20 restoration to
A20-deficient lymphoma cells demonstrates that targeting A20
may be harmful for other tumor types. As we do not fully
intermediate expression. An asterisk (*) indicates p,0.009 with log-rank analysis of survival curves for up-regulated versus down-regulated
expressing groups. (C) A20 mRNA expression was not associated with survival in glioblastoma patients in REMBRANDT. Eight patients exhibited a 2-
fold elevation in mRNA, whereas 27 patients were classified as having down-regulated expression and 74 with intermediate expression. p,0.68 with
log-rank analysis of survival curves for up-regulated versus down-regulated expressing groups. (D) The median intensity of A20 expression is
increased in glioblastoma patient samples in REMBRANDT in comparison to all other types of brain tumors when two different probesets are used. (E)
A 3-fold change in A20 (6q23.3) gene amplification was associated with reduced glioma patient survival in REMBRANDT. Four patients exhibited
amplification of the A20 gene compared to 196 intermediate expressing patients. An asterisk (*) indicates p,0.0269 with log-rank analysis of survival
curves for up-regulated versus intermediate expressing groups.
doi:10.1371/journal.pbio.1000319.g008
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effects on tumor growth and cancer cell behaviors, further
elucidation of A20 molecular and biological signals is warranted.
Materials and Methods
Ethics Statement
Primary human brain tumor patient specimens were obtained
from patients providing informed consent under protocols
approved by the Duke University or Cleveland Clinic Institutional
Review Boards. All animal experiments were performed in
accordance with a Duke University or Cleveland Clinic Institu-
tional Animal Care and Use Committee–approved protocol.
Isolation and Culture of Matched GSCs and Non-Stem
Glioma Cells
As previously described [11,12,15,21,23,25], matched cultures
enriched or depleted for GSCs were isolated from primary human
brain tumor patient specimens directly or those passaged short
term in immunocompromised mice. A Papain Dissociation System
(Worthington Biochemical) was used to dissociate tumors
according to the manufacturer’s instructions (detailed protocol:
http://www.worthington-biochem.com/PDS/default.html). Cells
were then cultured in Neurobasal medium supplemented with B27
without vitamin A, L-glutamine, sodium pyruvate (Invitrogen),
10 ng/ml basic fibroblast growth factor (bFGF), and 10 ng/ml
epidermal growth factor (EGF) (R&D Systems) for at least 6 h to
recover surface antigens. Cells were then labeled with an
allophycocyanin (APC)-conjugated CD133 antibody (Miltenyi
Biotec), and sorted by fluorescence-activated cell sorting (FACS).
Alternatively, cells were separated microbead-conjugated CD133
antibodies and magnetic columns (Miltenyi Biotec). CD133-
positive cells were designated as GSCs whereas CD133-negative
cells were designated as non-stem glioma cells. Consistent with
previously defined methods for GSC and non-GSC cell culture
[10], GSCs were cultured in the earlier-defined medium: matched
non-stem glioma cells were cultured for at least 24 h in 10% serum
containing DMEM to allow cell survival. After recovery, DMEM
medium was removed and the cells cultured in supplemented
Neurobasal medium for at least 12 h before experiments were
performed in identical medium. The cancer stem cell nature of the
CD133-positive cells was confirmed by fluorescent in situ
hybridization (FISH) analysis, serial neurosphere assays, and
tumor formation assays, but cultures depleted of cancer stem cells
did not self-renew and or initiate tumors (unpublished data).
Real-Time PCR
Total RNA was prepared using the RNeasy kit (Qiagen), and
reverse transcribed into cDNA using a SuperScript III First-Strand
Synthesis Kit (Invitrogen). To investigate expression of A20 and
Olig2, individual gene primers were ordered from Integrated DNA
technologies and Master Mixes were purchased from SuperArray
Bioscience Corporation. mRNA levels were measured using an
ABI-7900 system (Applied Biosystems). Sequences for primer sets
were as follows:
A20: Forward 59-AGT GTT CCC AGG TGG CCT TAG
AAA-39; Reverse 59-TCT CAG CCA AGA CGA TGA AGC
AGT-39. Olig2: Forward 59-GGT AAG TGC GCA ATG GTA
AGC TGT-39; Reverse 59-TAC AAA GCC CAG TTT GCA
ACG CAG-39.
Immunofluorescence Staining
Cells, neurospheres, or tumor sections were fixed with 4%
paraformaldehyde, washed with Tris-buffered saline, and incu-
bated with polyclonal mouse anti-A20 (Santa Cruz Biotechnology)
and goat anti-Sox2 (Santa Cruz Biotechnology) where indicated.
Primary antibodies were incubated for 16 h at 4uC followed by
detection with Alexa 488 donkey anti-mouse (Invitrogen) and
Alexa 568 donkey anti-rabbit (Invitrogen) secondary antibodies.
Nuclei were stained with Hoechst 33342 (Invitrogen), and slides
were mounted using Fluoromount (Calbiochem). Images were
taken with a Leica SP-5 confocal microscope.
Western Blotting and Antibodies
Equal amounts of cell lysate were resolved by SDS-PAGE,
transferred to polyvinylidene difluoride membranes (Millipore), and
detected using an enhanced chemiluminescence system (Pierce
Biotechnology) with antibodies against A20 (Abcam or Santa Cruz
Biotechnology), Olig2 (R&D Systems), and Tubulin (Sigma).
FACS Analysis for CD133 and A20 Costaining
Tumors were dissociated as described earlier and bulk or
isolated GSCs, and non-stem glioma cells were fixed in 4%
paraformaldehyde and subjected to FACS analysis. FACS analysis
was performed on a FACS Aria with 100-mm nozzle and low
sheath pressure. Human-specific anti-CD133 (293C3) conjugated
to allophycocyanin5 (APC) (Miltenyi) was used with anti–A20-PE
generated using the Lightning-Link PE kit (Innova Biosciences) in
combination with an A20 antibody (Abcam).
Lentiviral-Mediated shRNA Targeting
Lentiviral shRNA clones (Sigma Mission RNAi) targeting A20
and a scrambled nontargeting control (SHC002) were purchased
from Sigma. These vectors were cotransfected with the packaging
vectors psPAX2 and pCI-VSVG (Addgene) or the ViraPower
Lentiviral Expression System packaging mix (Invitrogen) into
293FT cells by Lipofectamine 2000 (Invitrogen) to produce the
virus. Efficiency of different lentiviral shRNA clones in cells was
determined by Western blot analysis and real-time PCR. The
sequence of the shRNAs utilized for shRNA1 (NM_006290.2-
635s1c1), shRNA2 (NM_006290.2-2104s1c1), and shNRA3







GSCs infected with lentivirus expressing the indicated shRNAs
for 24 h were plated in 96-well plates at 1,000 cells per well. Cell
titers were determined after the indicated number of days after
plating using the CellTiter-Glo Luminescent Cell Viability Assay
kit (Promega).
Cell-Cycle Analysis and Annexin V Staining
GSCs plated in six-well plates at 100,000 cells per well were
infected with lentivirus expressing the indicated shRNAs for
48 hours. To determine the percentage of cells in each phase of the
cell cycle, cells were fixed with ethanol and stained with propidium
iodide followed by cell-cycle analysis. To detect apoptotic cells,
Annexin V-FITC staining was performed with the Annexin V-FITC
Apoptosis Detection Kit (BD Pharmingen) according to the
manufacturer’s instructions. For experiments in which GSCs and
matched non-stem glioma cells were treated with TNFa,c e l l sw e r e
plated at a density of 100,000 cells per well in a six-well plate and
t r e a t e df o r7 2hw i t h5n g / m lT N F a.
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GSCs infected with lentivirus expressing the indicated shRNAs
for 24 h were plated at 1,000 cells per well and caspase 3/7
activity measured with a commercially available kit (Promega)
after an additional 24 h. Relative caspase activity was then
determined by correcting for cell titers determined as indicated
above. When TNFa treatment was combined with shRNA
treatments, cells were infected with lentivirus expressing the
indicated shRNAs for 24 h followed by TNFa treatment for 24 h.
TUNEL Staining
GSCs infected with lentivirus expressing the indicated shRNAs
for 36 h were stained for TUNEL using an Apo-BrdU-Red In Situ
DNA Fragmentation Assay Kit (Biovision) according to the
manufacturer’s instructions.
Neurosphere Formation Assay and Quantification of
Neurosphere Volume
GSCs infected with lentivirus expressing the indicated shRNAs
for 24 h were plated in 24-well plates at 10 cells per well and the
percentage of wells containing neurospheres quantified at
indicated times. For secondary sphere formation, neurosphere
forming cells from the first plating were trypsinized and plated at
10 cells per well in 24-well plates. Neurospheres were imaged with
an Olympus CK40 digital camera mounted to a light microscope
and neurosphere size was calculated using ImageJ software. When
TNFa treatment was combined with shRNA treatments, cells were
infected with lentivirus expressing the indicated shRNAs for 24 h
followed by treatment with 5 ng/ml TNFa treatment.
Intracranial Tumor Assays
Intracranial transplantation of GSCs into nude mice was
performed as described [11,12,15,23,25] in accordance with a
Duke University or Cleveland Clinic Institutional Animal Care and
Use Committee approved protocol. Briefly, 36 h after lentiviral
infection, cells were counted and the indicated number of live cells
implanted into the right frontal lobes of athymic nude mice. Mice
were maintained until the development of neurological signs.
Statistical Analysis
Significance was tested by t-test or ANOVA using GraphPad
InStat 3.0 software. For repeated measures ANOVA and in vivo
studies where Kaplan-Meier curves and log-rank analysis were
performed, MedCalc software was used.
Supporting Information
Figure S1 A20 is elevated in SSEA-1+ fractions of human
glioma cells where SSEA-1, but not CD133, is informa-
tive for tumorigenic potential. Equal amounts of lysates from
the human glioma cell lines 1228 and 905 sorted for the expression
of SSEA-1 were probed for the expression of A20 by Western blot.
a-Tubulin was utilized as a loading control.
Found at: doi:10.1371/journal.pbio.1000319.s001 (0.06 MB TIF)
Figure S2 Flow cytometry demonstrates A20 colocalizes
with a glioma stem cell marker. (A and B) Flow cytometry of
fixed bulk tumor cells isolated directly from T3832 (A) or T3946
(B) patient specimens demonstrates significant co-staining of the
glioma stem cell marker CD133 and A20. (C and D) Flow
cytometry analysis of glioma stem cell-enriched (C) and -depleted
(D) cultures from a T4105 patient specimen passaged short term in
immunocompromised mice demonstrates passage of cells in vitro
maintains coexpression of the glioma stem cell marker CD133 and
A20 in glioma stem cells with reduced CD133 and A20 expression
in non-stem glioma cells.
Found at: doi:10.1371/journal.pbio.1000319.s002 (1.83 MB TIF)
Figure S3 A20 preferentially decreases the growth of
glioma stem cells. Cell growth as measured with Trypan Blue
staining demonstrated that A20 shRNA decreases the growth of
non-stem glioma cells isolated from T4121 (A) or T08-836 cells
(B). An asterisk (*) indicates p,0.01 with ANOVA comparison to
non-targeting shRNA. Matched glioma stem cells with A20
targeting are shown in Figure 3C and 3D. When the fold change
in cell numbers relative to the average non-targeting shRNA cell
number is calculated for T4121 (C and D) or T08-837 (E and F)
cells, targeting with A20 shRNA1 (C and E) or A20 shRNA3 (D
and F) demonstrates significantly greater reductions in cell number
in the glioma stem cell fractions. An asterisk (*) indicates p,0.001
with t-test comparison to non-stem glioma cells.
Found at: doi:10.1371/journal.pbio.1000319.s003 (0.47 MB TIF)
Figure S4 A20 protects GSCs from TNFa-induced apo-
ptosis. GSC enriched cultures isolated from a T4597 glioma
xenograft were infected with non-targeting shRNA or shRNA
directed against A20 and treated with 5 ng/ml TNFa.( A )R e l a t i v e
caspase activity increased with A20 knockdown and was further
increased by TNFa treatment. (B) Neurosphere formation decreased
with A20 knockdown and was further decreased by TNFa treatment.
An asterisk (*) indicates p,0.05 with ANOVA comparison to
similarly treated nontargeting control cells. A number sign (#)
indicates p,0.05 with ANOVA comparison of TNF to untreated
cells infected with the same shRNA.
Found at: doi:10.1371/journal.pbio.1000319.s004 (0.13 MB TIF)
Figure S5 Tumors resulting from implantation of A20
knockdown GSCs express A20. Immunofluorescence of
paraffin-embedded sections of tumors resulting from implantation
of GSCs infected with nontargeting shRNA or A20 shRNA1
demonstrates A20 is expressed in both tumor types.
Found at: doi:10.1371/journal.pbio.1000319.s005 (0.41 MB TIF)
Figure S6 Glioblastoma genetic subsets and expression
of A20. (A) Table demonstrating the number of samples in the
TCGA database analyzed as having low, intermediate, or high
A20 expression. The number of samples in each group indicated
as having mutations in p53, EGFR, PTEN, or NF1 is also shown.
(B) Analysis of the percentage of patients with mutations in p53,
EGFR, PTEN, or NF1 for the groups have differential A20
expression is shown. The percentage of patients with p53 or NF1
mutations is increased in the set of patients with high A20
expression. (C) Some TNFa signaling mediator mRNAs are
elevated in the set of patients with high A20 expression. Analysis of
the expression of multiple TNF receptor and NF-kB family
members demonstrated elevated expression was often observed in
patient samples with elevated A20.
Found at: doi:10.1371/journal.pbio.1000319.s006 (0.51 MB TIF)
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